Yumna Khabir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yumna Khabir has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Mahnoor Rehan Hashmi
Dow Medical College, Dow University of Health Sciences, Baba-e-Urdu Road, Karachi, 74200, Pakistan
6 shared publications - Adam Ali Asghar
Department of Medicine, Dow University of Health Sciences, Mission Rd, New Labour Colony Nanakwara, Karachi, Sindh, Pakistan
4 shared publications - Ali Ahmed
Division of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego (UCSD), San Diego, USA
1 shared publication - Areeba Ikram
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Ayesha Azhar
Department of Internal Medicine, Dow University of Health Sciences
1 shared publication - Ayesha Shaukat
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 18 August 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (6) , 1712-1721
Reduced‐Port Versus Multi‐Port Laparoscopic Colectomy for Colorectal Cancer: A Systematic Review, Meta‐Analysis, and Meta‐Regression
Background: Reduced‐port laparoscopic colectomy (RPLC) has emerged as an alternative to multi‐port laparoscopic colectomy (MPLC) for colorectal cancer surgery, aiming to reduce operative morbidity and improve cosmetic outcomes. This systematic review and meta‐analysis evaluated and compared operative, postoperative, and oncologic outcomes between RPLC and MPLC. Methods: Following PRISMA guidelines, we systematically searched PubMed, Cochrane Library, ScienceDirect, and Google Scholar from inception to June 2025. The protocol was registered on PROSPERO (CRD420251078328). Included studies were randomized controlled trials (RCTs) or cohort studies comparing RPLC and MPLC. Primary outcomes were estimated blood loss, operative time, hospital stay, lymph node yield, and postoperative recovery indicators. Secondary outcomes included conversion rates, complications, and Clavien‐Dindo graded adverse events. Risk of bias was evaluated using the Newcastle‐Ottawa Scale and Cochrane RoB 2.0 tool. A random‐effects meta‐regression was performed to explore the impact of high‐stage tumors on the outcomes. Results: Thirteen studies ( n = 2897) were included. RPLC significantly reduced operative time (MD: −19.98 min; 95% CI: −29.73 to −10.24, p < 0.0001) and estimated blood loss (MD: −13.70 mL; 95% CI: −25.63 to −1.77, p = 0.02) without compromising hospital stay, lymph node yield, or complication rates. Meta‐regression revealed tumor stage significantly influenced operative time ( p = 0.0013). Conclusions: RPLC appears to provide comparable postoperative outcomes to MPLC with modest intraoperative advantages. As the evidence is largely retrospective and heterogeneous, these findings indicate the feasibility of RPLC rather than its superiority over MPLC. High‐quality clinical trials with longer follow‐up are required to confirm these findings and optimize clinical decision‐making. Trial Registration: PROSPERO registration ID: CRD420251078328
- 18 August 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (6) , 1712-1721
Open AccessReduced‐Port Versus Multi‐Port Laparoscopic Colectomy for Colorectal Cancer: A Systematic Review, Meta‐Analysis, and Meta‐Regression
Background: Reduced‐port laparoscopic colectomy (RPLC) has emerged as an alternative to multi‐port laparoscopic colectomy (MPLC) for colorectal cancer surgery, aiming to reduce operative morbidity and improve cosmetic outcomes. This systematic review and meta‐analysis evaluated and compared operative, postoperative, and oncologic outcomes between RPLC and MPLC. Methods: Following PRISMA guidelines, we systematically searched PubMed, Cochrane Library, ScienceDirect, and Google Scholar from inception to June 2025. The protocol was registered on PROSPERO (CRD420251078328). Included studies were randomized controlled trials (RCTs) or cohort studies comparing RPLC and MPLC. Primary outcomes were estimated blood loss, operative time, hospital stay, lymph node yield, and postoperative recovery indicators. Secondary outcomes included conversion rates, complications, and Clavien‐Dindo graded adverse events. Risk of bias was evaluated using the Newcastle‐Ottawa Scale and Cochrane RoB 2.0 tool. A random‐effects meta‐regression was performed to explore the impact of high‐stage tumors on the outcomes. Results: Thirteen studies ( n = 2897) were included. RPLC significantly reduced operative time (MD: −19.98 min; 95% CI: −29.73 to −10.24, p < 0.0001) and estimated blood loss (MD: −13.70 mL; 95% CI: −25.63 to −1.77, p = 0.02) without compromising hospital stay, lymph node yield, or complication rates. Meta‐regression revealed tumor stage significantly influenced operative time ( p = 0.0013). Conclusions: RPLC appears to provide comparable postoperative outcomes to MPLC with modest intraoperative advantages. As the evidence is largely retrospective and heterogeneous, these findings indicate the feasibility of RPLC rather than its superiority over MPLC. High‐quality clinical trials with longer follow‐up are required to confirm these findings and optimize clinical decision‐making. Trial Registration: PROSPERO registration ID: CRD420251078328
- 29 August 2025
- Published by One Surgery
- No. 1
Late, Too Often: Disproportionate Mortality and Late-Stage Diagnosis in U.S. Pancreatic Cancer (A Nationwide Analysis Using SEER and CDC WONDER Data)
Introduction Pancreatic cancer is one of the deadliest malignancies in the United States, with an alarmingly low 5-year survival rate of 12.8%. Despite accounting for only 3.3% of new cancer cases in 2024, it contributes to 8.5% of all cancer-related deaths. This study evaluates trends in pancreatic cancer incidence, survival, and mortality. Methods Death-specific data from CDC WONDER (1999–2020) were analyzed to track age-adjusted mortality rates, while SEER data (2014–2020) provided insights into 5-year relative survival rates, stage at diagnosis, and demographic disparities. Results: Between 2017–2021, the age-adjusted incidence of pancreatic cancer was 13.5, with an AAMR of 11.2 (2018–2022). The 5-year survival rate was 12.8%, with 51% diagnosed at a distant stage, where survival drops to 3%, while early detection at a localized stage (14%) improves survival to 44%. From 1999 to 2020, total deaths rose by over 60% (29,082 to 46,774), though AAMR remained relatively stable (10.54 to 11.07), reflecting population aging. Racial disparities were evident: Black individuals had higher distant-stage diagnoses (50.2%), while Asian/Pacific Islanders showed the best survival (14.8%). Males had higher AAMR (19.35) than females (14.72), and Louisiana recorded the highest state-level AAMR (19.32). Conclusion Despite modest improvements in survival, disparities persist. Strengthening surgical systems requires early detection, equitable access to care, and collaboration across health sectors. Targeted screening, culturally sensitive outreach, and data-driven reforms are key to reducing the burden of pancreatic cancer.
- 29 August 2025
- Published by One Surgery
- No. 1
Late, Too Often: Disproportionate Mortality and Late-Stage Diagnosis in U.S. Pancreatic Cancer (A Nationwide Analysis Using SEER and CDC WONDER Data)
Introduction Pancreatic cancer is one of the deadliest malignancies in the United States, with an alarmingly low 5-year survival rate of 12.8%. Despite accounting for only 3.3% of new cancer cases in 2024, it contributes to 8.5% of all cancer-related deaths. This study evaluates trends in pancreatic cancer incidence, survival, and mortality. Methods Death-specific data from CDC WONDER (1999–2020) were analyzed to track age-adjusted mortality rates, while SEER data (2014–2020) provided insights into 5-year relative survival rates, stage at diagnosis, and demographic disparities. Results: Between 2017–2021, the age-adjusted incidence of pancreatic cancer was 13.5, with an AAMR of 11.2 (2018–2022). The 5-year survival rate was 12.8%, with 51% diagnosed at a distant stage, where survival drops to 3%, while early detection at a localized stage (14%) improves survival to 44%. From 1999 to 2020, total deaths rose by over 60% (29,082 to 46,774), though AAMR remained relatively stable (10.54 to 11.07), reflecting population aging. Racial disparities were evident: Black individuals had higher distant-stage diagnoses (50.2%), while Asian/Pacific Islanders showed the best survival (14.8%). Males had higher AAMR (19.35) than females (14.72), and Louisiana recorded the highest state-level AAMR (19.32). Conclusion Despite modest improvements in survival, disparities persist. Strengthening surgical systems requires early detection, equitable access to care, and collaboration across health sectors. Targeted screening, culturally sensitive outreach, and data-driven reforms are key to reducing the burden of pancreatic cancer.
- 29 August 2025
- Published by One Surgery
- No. 1
Epidemiologic Trends and Disparities in Esophageal Cancer in the U.S.: A SEER and CDC WONDER Analysis
Background and Objective: Esophageal cancer remains a highly fatal malignancy with notable disparities based on sex and race. This study aimed to assess recent trends in incidence, stage at diagnosis, survival outcomes, and mortality in the U.S., with a focus on demographic disparities. Methods: Data from the SEER Program (2017–2021) were used to assess incidence across sex, race/ethnicity, subtype, and stage. Five-year survival (2014–2020) was analyzed by demographic factors and stage. Mortality trends (1999–2020) were evaluated using CDC WONDER death certificate data, stratified by race and gender. Results: Esophageal cancer incidence was 4.2/100,000—higher in males (7.1) than females (1.7). American Indian/Alaska Natives had the highest rates (5.2) whereas Asian/Pacific Islanders the lowest (2.2). Adenocarcinoma was the predominant subtype (2.7), followed by squamous cell carcinoma (1.1). Most cases were diagnosed at regional (1.3) or distant stages (1.5). 5-year survival was higher in females (21.6%) and highest at localized stage (48.1%). Survival varied by race, lowest in American Indian (14.8%). Age-adjusted mortality (AAMR) declined from 4.36 in 1999 to 3.67 in 2020. Male AAMRs peaked in 2001 (7.83) and declined to 6.45 (2020); female AAMRs peaked the same year (1.78→1.36). Overall (1999–2020), rates were 7.31 (males) vs 1.56 (females), with 4.7× higher mortality in men. Mortality among Black/African Americans decreased significantly, narrowing racial gaps. Conclusion: Findings underscore the need for transdisciplinary efforts integrating epidemiology, surgical oncology, policy, and community outreach. Culturally tailored screening, equitable surgical access, and workforce diversity are key to strengthening surgical systems.
- 29 August 2025
- Published by One Surgery
- No. 1
Epidemiologic Trends and Disparities in Esophageal Cancer in the U.S.: A SEER and CDC WONDER Analysis
Background and Objective: Esophageal cancer remains a highly fatal malignancy with notable disparities based on sex and race. This study aimed to assess recent trends in incidence, stage at diagnosis, survival outcomes, and mortality in the U.S., with a focus on demographic disparities. Methods: Data from the SEER Program (2017–2021) were used to assess incidence across sex, race/ethnicity, subtype, and stage. Five-year survival (2014–2020) was analyzed by demographic factors and stage. Mortality trends (1999–2020) were evaluated using CDC WONDER death certificate data, stratified by race and gender. Results: Esophageal cancer incidence was 4.2/100,000—higher in males (7.1) than females (1.7). American Indian/Alaska Natives had the highest rates (5.2) whereas Asian/Pacific Islanders the lowest (2.2). Adenocarcinoma was the predominant subtype (2.7), followed by squamous cell carcinoma (1.1). Most cases were diagnosed at regional (1.3) or distant stages (1.5). 5-year survival was higher in females (21.6%) and highest at localized stage (48.1%). Survival varied by race, lowest in American Indian (14.8%). Age-adjusted mortality (AAMR) declined from 4.36 in 1999 to 3.67 in 2020. Male AAMRs peaked in 2001 (7.83) and declined to 6.45 (2020); female AAMRs peaked the same year (1.78→1.36). Overall (1999–2020), rates were 7.31 (males) vs 1.56 (females), with 4.7× higher mortality in men. Mortality among Black/African Americans decreased significantly, narrowing racial gaps. Conclusion: Findings underscore the need for transdisciplinary efforts integrating epidemiology, surgical oncology, policy, and community outreach. Culturally tailored screening, equitable surgical access, and workforce diversity are key to strengthening surgical systems.
- Open Access
- 25 June 2025
- Published by Health Services Academy in Pakistan Journal of Public Health
- Vol. 15 (2) , 31-32
South Asia’s Deadly Kite Strings: Public Safety Risks, Legal Gaps, and Policy Solutions
“Our Asif is gone; don’t let anyone else’s Asif go,” said the grieving family of 22-year-old Asif Ashfaq, who, while riding his motorcycle in Faisalabad in March 2024, was fatally injured when a stray kite string severed his neck (1). This tragedy is not isolated; it highlights a longstanding public safety concern during kite festivals such as Basant in Pakistan and Makar Sankranti in India. Despite recurrent fatalities, the epidemiology of such injuries remains poorly documented due to limited surveillance and underreporting. During these annual festivals, the use of manjha, a glass-coated thread, causes severe neck lacerations, bleeding, and airway obstruction. The goal of the festival is to cut opponents' kite strings, but this practice unintentionally puts lives at risk. Recognizing the dangers associated with hazardous kite strings, both India and Pakistan have implemented regulations to curb their use. In Pakistan, the Punjab Prohibition of Kite Flying (Amendment) Act 2025 establishes a province-wide ban and significantly increases penalties: kite flyers may face three to five years’ imprisonment and fines up to PKR 2 million, while manufacturers and suppliers face higher penalties (up to seven years’ imprisonment and fines up to PKR 5 million) (2). Similar penalties exist in India, particularly in Delhi. In Faisalabad, local authorities launched a zero-tolerance policy that led to over 2,710 cases, 2,715 arrests, and the seizure of over 250,000 kites and 7,200 bundles of kite strings (3). Additionally, safety measures such as metallic frames for motorcyclists have been introduced as an attempt to prevent further injuries (4).
- 25 June 2025
- Published by Health Services Academy in Pakistan Journal of Public Health
- Vol. 15 (2) , 31-32
Open AccessSouth Asia’s Deadly Kite Strings: Public Safety Risks, Legal Gaps, and Policy Solutions
“Our Asif is gone; don’t let anyone else’s Asif go,” said the grieving family of 22-year-old Asif Ashfaq, who, while riding his motorcycle in Faisalabad in March 2024, was fatally injured when a stray kite string severed his neck (1). This tragedy is not isolated; it highlights a longstanding public safety concern during kite festivals such as Basant in Pakistan and Makar Sankranti in India. Despite recurrent fatalities, the epidemiology of such injuries remains poorly documented due to limited surveillance and underreporting. During these annual festivals, the use of manjha, a glass-coated thread, causes severe neck lacerations, bleeding, and airway obstruction. The goal of the festival is to cut opponents' kite strings, but this practice unintentionally puts lives at risk. Recognizing the dangers associated with hazardous kite strings, both India and Pakistan have implemented regulations to curb their use. In Pakistan, the Punjab Prohibition of Kite Flying (Amendment) Act 2025 establishes a province-wide ban and significantly increases penalties: kite flyers may face three to five years’ imprisonment and fines up to PKR 2 million, while manufacturers and suppliers face higher penalties (up to seven years’ imprisonment and fines up to PKR 5 million) (2). Similar penalties exist in India, particularly in Delhi. In Faisalabad, local authorities launched a zero-tolerance policy that led to over 2,710 cases, 2,715 arrests, and the seizure of over 250,000 kites and 7,200 bundles of kite strings (3). Additionally, safety measures such as metallic frames for motorcyclists have been introduced as an attempt to prevent further injuries (4).
- Open Access
- 28 March 2025
- Published by Springer Nature in Discover Public Health
- Vol. 22 (1) , 1-3
Cupping the future: highlighting the importance of menstrual cups and the prevailing challenges to its use in Pakistani women
- 28 March 2025
- Published by Springer Nature in Discover Public Health
- Vol. 22 (1) , 1-3
Open AccessCupping the future: highlighting the importance of menstrual cups and the prevailing challenges to its use in Pakistani women
- Open Access
- 4 October 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (11) , 5584-5592
Odds of HIV among incarcerated drug users: a systematic review and meta-analysis of Asian countries
Background: HIV makes up a large portion of infectious diseases globally. People injecting drugs in prisons are at high risk for contracting HIV infection. Prisons house ~10.2 million people globally, making them a high-risk setting for HIV transmission. This systematic review summarizes the available data on the odds of developing HIV infection among imprisoned people who inject drugs (PWIDs) in Asian regions. Methods: The authors electronically assessed published studies from January, 2000 to December, 2022, including studies that investigated the odds of HIV in imprisoned PWIDs. We extensively searched PubMed, ERIC, and Cochrane Central and Google Scholar with no constraints in language or time. All the observational studies evaluating the chances of HIV in Asian prisoners with an exposure group of PWIDs and a control group of non-injecting-drug users were included in our analysis. Results: The databases search yielded 254 potential studies, 10 observational studies of which having a total of 17 333 participants were included. A low or moderate risk of bias was reported in all the studies except one case-control. The pooled analysis showed a significant association between PWIDs and the chances of contracting HIV infection (Odds ratio=6.40; 95% CI=3.89–10.52; P2=53%). Conclusion: This study found a vital correlation between injecting-drug usage during imprisonment and HIV transmission speed. The results of this meta-analysis support the need to prevent HIV and conducting treatment programs in high-risk settings like prisons.
- 4 October 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (11) , 5584-5592
Open AccessOdds of HIV among incarcerated drug users: a systematic review and meta-analysis of Asian countries
Background: HIV makes up a large portion of infectious diseases globally. People injecting drugs in prisons are at high risk for contracting HIV infection. Prisons house ~10.2 million people globally, making them a high-risk setting for HIV transmission. This systematic review summarizes the available data on the odds of developing HIV infection among imprisoned people who inject drugs (PWIDs) in Asian regions. Methods: The authors electronically assessed published studies from January, 2000 to December, 2022, including studies that investigated the odds of HIV in imprisoned PWIDs. We extensively searched PubMed, ERIC, and Cochrane Central and Google Scholar with no constraints in language or time. All the observational studies evaluating the chances of HIV in Asian prisoners with an exposure group of PWIDs and a control group of non-injecting-drug users were included in our analysis. Results: The databases search yielded 254 potential studies, 10 observational studies of which having a total of 17 333 participants were included. A low or moderate risk of bias was reported in all the studies except one case-control. The pooled analysis showed a significant association between PWIDs and the chances of contracting HIV infection (Odds ratio=6.40; 95% CI=3.89–10.52; P2=53%). Conclusion: This study found a vital correlation between injecting-drug usage during imprisonment and HIV transmission speed. The results of this meta-analysis support the need to prevent HIV and conducting treatment programs in high-risk settings like prisons.
- 8 September 2023
- Published by Elsevier in The Lancet
- Vol. 402 (10405) , 849-850
Pakistan's economic and health crisis: calls for urgent action
- 8 September 2023
- Published by Elsevier in The Lancet
- Vol. 402 (10405) , 849-850
Pakistan's economic and health crisis: calls for urgent action
- Open Access
- 16 August 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 4909-4912
Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review
Multiple sclerosis (MS) is a chronic systemic autoimmune disorder characterized by plaques of demyelination, autoimmune inflammation, and astrocytic gliosis. The primary cells involved in the pathophysiology of MS are T cells. However, B cells have recently been implicated in the pathophysiology of the disease. Therefore, researchers have been exploring B cell therapy as an alternative treatment option for MS. B cell therapy is based on the targeted depletion of CD20-positive B cells. Rituximab, ocrelizumab, and ofatumumab are anti-CD20 antibodies already approved. Briumvi, the fourth type of anti-CD20 antibody was approved by FDA in December 2022, for the treatment of relapsing types of MS, including relapsing-remitting multiple sclerosis, active secondary progressive multiple sclerosis, and clinically isolated syndromes after the drug was tested in two randomized, double-blind, phase III, ULTIMATE I, and II trials which compared Briumvi (ublituximab) with Aubiago (teriflunomide). Ublituximab was found to have a much lower annual relapse rate in the ULTIMATE II trials than teriflunomide. Briumvi is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Its mechanism of action involves several distinct processes that collectively lead to the depletion of B cells and suppression of the immune response. The primary mode of action of Briumvi is its high-affinity binding to CD20. Infusion-related reactions are the most common side effects encountered following intravenous administration of ublituximab.
- 16 August 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 4909-4912
Open AccessBriumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review
Multiple sclerosis (MS) is a chronic systemic autoimmune disorder characterized by plaques of demyelination, autoimmune inflammation, and astrocytic gliosis. The primary cells involved in the pathophysiology of MS are T cells. However, B cells have recently been implicated in the pathophysiology of the disease. Therefore, researchers have been exploring B cell therapy as an alternative treatment option for MS. B cell therapy is based on the targeted depletion of CD20-positive B cells. Rituximab, ocrelizumab, and ofatumumab are anti-CD20 antibodies already approved. Briumvi, the fourth type of anti-CD20 antibody was approved by FDA in December 2022, for the treatment of relapsing types of MS, including relapsing-remitting multiple sclerosis, active secondary progressive multiple sclerosis, and clinically isolated syndromes after the drug was tested in two randomized, double-blind, phase III, ULTIMATE I, and II trials which compared Briumvi (ublituximab) with Aubiago (teriflunomide). Ublituximab was found to have a much lower annual relapse rate in the ULTIMATE II trials than teriflunomide. Briumvi is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Its mechanism of action involves several distinct processes that collectively lead to the depletion of B cells and suppression of the immune response. The primary mode of action of Briumvi is its high-affinity binding to CD20. Infusion-related reactions are the most common side effects encountered following intravenous administration of ublituximab.
- Open Access
- 1 January 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (1) , 41-42
The application of extended reality in cardiac surgery: potential implications for low- and middle-income countries
- 1 January 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (1) , 41-42
Open AccessThe application of extended reality in cardiac surgery: potential implications for low- and middle-income countries
- 17 November 2022
- Published by Elsevier in The Lancet Psychiatry
- Vol. 9 (12) , e52-E52
The neglect of male post-partum depression in Pakistan
- 17 November 2022
- Published by Elsevier in The Lancet Psychiatry
- Vol. 9 (12) , e52-E52
The neglect of male post-partum depression in Pakistan